Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowThe $70 million investment is the latest in a string of moves by the Indianapolis-based drugmaker to bulk up its hometown presence. In 2013, the company launched a $400 million expansion of its insulin manufacturing operations.
The facility will be built along Morris street at the Lilly Technology Center-North campus, next to Lilly building K301.
The new building will feature a multi-disciplinary laboratory that facilitates collaboration across multiple research areas.
Lilly employs 4,400 R&D workers in Indianapolis, the biggest chunk of its 7,000 R&D employees worldwide. The company said there were no jobs currently planned for this expansion.
"However, we are always reevaluating our staffing needs so that we can best support our business," a Lilly spokeswoman told IBJ in an email. "For instance, we’ve added 100 additional jobs as a part of our 2013 expansion, beyond our original commitment."
Lilly has applied for a real-property tax abatement on the proposed expansion that will save it $6.6 million over a 10-year abatement period, the Department of Metropolitan Development disclosed Monday.
Lilly will still pay about $6.7 million in property taxes during the abatement period on the increased value of the property, plus another $11.8 million it is paying now on the existing property. After the abatement period, Lilly will pay an estimated $1.3 million annually in property on the improvements.
Lilly said the tax break would help it retain 175 employees involved in insulin production making an average wage of $31 per hour.
The tax-break request will go before the Metropolitan Development Commission on Wednesday for preliminary approval. It would also require City-Council approval before coming back to the MDC for final approval Nov. 18.
Please enable JavaScript to view this content.